{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=77&state=Wisconsin",
    "query": {
      "state": "Wisconsin",
      "city": "Milwaukee",
      "page": 77
    },
    "page_size": 10
  },
  "pagination": {
    "page": 77,
    "page_size": 10,
    "total_count": 5351,
    "total_pages": 536,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=78&state=Wisconsin&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=76&state=Wisconsin&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T19:04:30.639Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02842086",
      "title": "Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pre-Exposure Prophylaxis of HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "F/TDF",
          "type": "DRUG"
        },
        {
          "name": "F/TAF Placebo",
          "type": "DRUG"
        },
        {
          "name": "F/TDF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5399,
      "start_date": "2016-09-02",
      "completion_date": "2026-07-29",
      "has_results": true,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-01T19:04:30.639Z",
      "location_count": 54,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Newport Beach, California + 38 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02842086"
    },
    {
      "nct_id": "NCT05327803",
      "title": "Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "MAC Lung Disease",
        "Treatment Refractory MAC Lung Disease"
      ],
      "interventions": [
        {
          "name": "Epetraborole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AN2 Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2022-05-20",
      "completion_date": "2024-12-18",
      "has_results": true,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-11-01T19:04:30.639Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05327803"
    },
    {
      "nct_id": "NCT00957996",
      "title": "Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seasonal Influenza",
        "Cough",
        "Sore Throat",
        "Nasal Congestion",
        "Myalgia",
        "Headache",
        "Fatigue"
      ],
      "interventions": [
        {
          "name": "Peramivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioCryst Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2009-10",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2015-02-12",
      "last_synced_at": "2026-11-01T19:04:30.639Z",
      "location_count": 79,
      "location_summary": "Dothan, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 76 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00957996"
    },
    {
      "nct_id": "NCT01307462",
      "title": "Targeted Therapy of Bronchiolitis Obliterans Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bronchiolitis Obliterans"
      ],
      "interventions": [
        {
          "name": "fluticasone propionate",
          "type": "DRUG"
        },
        {
          "name": "montelukast sodium",
          "type": "DRUG"
        },
        {
          "name": "azithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stephanie Lee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "6 Years to 99 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-06",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-10-04",
      "last_synced_at": "2026-11-01T19:04:30.639Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • Stanford, California • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01307462"
    },
    {
      "nct_id": "NCT00719303",
      "title": "Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "Fallopian Tube Mucinous Adenocarcinoma",
        "Fallopian Tube Serous Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Malignant Ovarian Brenner Tumor",
        "Ovarian Clear Cell Adenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Ovarian Serous Adenocarcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Stage IIA Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIA Ovarian Cancer AJCC V6 and v7",
        "Stage IIB Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIC Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Fallopian Tube Cancer AJCC v7",
        "Stage IIIA Ovarian Cancer AJCC v6 and v7",
        "Stage IIIA Primary Peritoneal Cancer AJCC v7",
        "Stage IIIB Fallopian Tube Cancer AJCC v7",
        "Stage IIIB Ovarian Cancer AJCC v6 and v7",
        "Stage IIIB Primary Peritoneal Cancer AJCC v7",
        "Stage IIIC Fallopian Tube Cancer AJCC v7",
        "Stage IIIC Ovarian Cancer AJCC v6 and v7",
        "Stage IIIC Primary Peritoneal Cancer AJCC v7",
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7",
        "Undifferentiated Fallopian Tube Carcinoma",
        "Undifferentiated Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Behavioral Dietary Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Compliance Monitoring",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Counseling",
          "type": "OTHER"
        },
        {
          "name": "Educational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Exercise Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1070,
      "start_date": "2012-06-18",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-02-19",
      "last_synced_at": "2026-11-01T19:04:30.639Z",
      "location_count": 687,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 452 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00719303"
    },
    {
      "nct_id": "NCT03163446",
      "title": "Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Staphylococcus Aureus Bacteremia",
        "Staphylococcus Aureus Endocarditis"
      ],
      "interventions": [
        {
          "name": "CF-301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ContraFect",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2017-05-23",
      "completion_date": "2019-03-07",
      "has_results": true,
      "last_update_posted_date": "2021-10-08",
      "last_synced_at": "2026-11-01T19:04:30.639Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03163446"
    },
    {
      "nct_id": "NCT01088503",
      "title": "Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "ADP receptor inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12227,
      "start_date": "2010-03",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2016-01-29",
      "last_synced_at": "2026-11-01T19:04:30.639Z",
      "location_count": 185,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 182 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fayetteville",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01088503"
    },
    {
      "nct_id": "NCT00408174",
      "title": "Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Inflammatory Bowel Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Balsalazide disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2006-05",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-11-01T19:04:30.639Z",
      "location_count": 88,
      "location_summary": "Tempe, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 74 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00408174"
    },
    {
      "nct_id": "NCT00063882",
      "title": "Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Brachytherapy (100/110)",
          "type": "RADIATION"
        },
        {
          "name": "Brachytherapy (125/145)",
          "type": "RADIATION"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 588,
      "start_date": "2003-06",
      "completion_date": "2022-12-22",
      "has_results": true,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-11-01T19:04:30.639Z",
      "location_count": 168,
      "location_summary": "Phoenix, Arizona • Auburn, California • Berkeley, California + 122 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Cameron Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00063882"
    },
    {
      "nct_id": "NCT02193282",
      "title": "Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Non-Squamous Non-Small Cell Carcinoma",
        "Stage IB Lung Non-Small Cell Carcinoma AJCC v7",
        "Stage II Lung Non-Small Cell Cancer AJCC v7",
        "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7",
        "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7",
        "Stage IIIA Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 390,
      "start_date": "2015-02-11",
      "completion_date": "2027-02-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-11-01T19:04:30.639Z",
      "location_count": 1403,
      "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02193282"
    }
  ]
}